2010

$99,984 exploratory grant from the National Institute of Health (NCCAM). One of the aims was to obtain an oxalate-reducing enzyme with ideal properties to be a potential drug candidate, medical food, or dietary supplement by screening 100-150 fungi species and selecting 2-10 species.

$150,788 exploratory grant from the National Institute of Health (NIDDK). One of the aims was to clone and express the two oxalate decarboxylase genes and establish manufacturing processes to produce sufficient amounts for formulation development.


2011

$50,000 Florida SBIR Matching Funds grant from the Institute for the Commercialization of Public Research (matching SBIR Phase I grant (1R43DK089720-01)).


2014

$1,258,172 SBIR Phase II grant from the National Institute of Health (NCCAM) with the aim of increasing enzyme activity to further reduce dose size, improving patient compliance, decreasing manufacturing costs, and starting pre-clinical studies.


2015

Aaron Cowley and Helena Cowley awarded Governor’s Entrepreneur Award 2015 for “excelling in the work place” and creating jobs through an innovative business.


2016

$1,008,124 SBIR Phase II grant from the National Institute of Health (NIDDK) with the aim of optimizing the current formulations for maximal activity at neutral pH and protease protection and scalability; as well as optimizing to demonstrate safety in a 90-day toxicology study.


2017

Captozyme was among fifty emerging companies elected as a Florida Company to Watch — an honor given to companies expected to experience significant growth in the coming years and that have demonstrated capacity and intent to grow.